Contract Development and Manufacturing Organization (CDMO) Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 243.29 Billion |
| Market Size (2029) | USD 331.98 Billion |
| CAGR (2024 - 2029) | 6.41 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Analysis
The Pharmaceutical Contract Development And Manufacturing Organization Market size is estimated at USD 243.29 billion in 2024, and is expected to reach USD 331.98 billion by 2029, growing at a CAGR of 6.41% during the forecast period (2024-2029).
Advanced manufacturing techniques and processes will help the CMO market grow. CMOs are expected to improve the efficiency of their manufacturing processes, minimizing waste and lowering costs, owing to new operational strategies, such as continuous manufacturing. The growth of small and mid-sized pharmaceutical firms, which are in charge of an expanding portion of new drug approvals and frequently lack manufacturing capacity, is anticipated to be a driving force behind CMOs adopting new manufacturing technologies.
- With the rise of personalized medicine, the industry is trying to make clinical trials more accessible and patient-friendly. Technology has become a key element in contract research organizations. CROs are at the forefront of implementing the newest technologies and tools to maintain a competitive edge and ensure they can provide customers with the full range of solutions. Adopting these new technologies has been helping CROs be more effective and increase research speed, driving the CRO market's growth.CROs continue to face challenges ranging from commoditization and changing patient engagement models to pressure from the competition. As larger companies share more market, market stratification forces smaller CROs to subcontract or niche down.
- Pharmaceutical outsourcing evolved from basic processes, namely bottling, to more value-added techniques, such as medical device engineering and R&D. The active process-outsourcing experience, the increase in patients subject to medical procedures, and the improvements in illness detection and diagnosis in developing countries are the factors propelling the growth of this market.
- There has been a gradual change in the working principles of the companies in the market. The pattern shift from cost-control to re-emphasis on value-added services has led to the redefining of CMOs to CDMOs (contract development and manufacturing organizations) and allowed their integration into the value chain of companies.
- The costs invested in R&D are continuously increasing, yet the valuable results from these processes are becoming rarer. Many companies have realized that moving this part of the business overseas and taking advantage of the still-emerging pharmaceutical markets effectively reduces costs. Despite the evidence regarding cost savings and competencies that can be accrued, many companies are reluctant to give up that control. However, the scenario is changing gradually. The pressure on reducing the length of the supply chain and improving lead-time efficiency is forcing the companies to take various measures to meet the demand, turning contract manufacturing into a bottleneck in the supply chain.
- The COVID-19 pandemic has exposed significant gaps in the global health systems and disrupted the distribution of medicines, particularly in low and middle-income countries. Governments and industries faced new access-to-medicine challenges as the COVID-19 control effort picked up speed, along with developing new COVID-19 medicines and distributing them worldwide at an unprecedented rate. The CMO/CDMO service industry was in a unique position to help drug developers overcome some of the difficulties brought on by the COVID-19 pandemic. The pandemic impacted the pharma and biopharma industries in many ways, including supply chain logistics, drug development, clinical trials, supplies, and manufacturing.
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Statistics
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market growth is not evenly distributed across regions. The US, China, India, and Germany are the largest country markets for Pharmaceuticals CDMO Market, however, many smaller country market segments are expected to register much higher growth compared to these giants. For example, the United States is one of the top three Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market but lags behind emerging economies such as India, Germany, and South Africa in terms of future growth.
United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market revenue in the United States was valued at USD 54.21 billion in 2023. It is expected to reach USD 68.32 billion by 2028, growing at a CAGR of 4.74% during the forecast period (2023-2028). United States contract manufacturing organizations (CMOs) have evolved from an initial offering of essential manufacturing services to a wide range of services to meet market and outsourcer demand. Steady growth in the U.S. pharmaceutical industry and increasing outsourcing by major pharmaceutical companies focusing on their core competencies to improve profit margins are driving the country's market.
-Market-Revenue-in-USD-Billion.png)
| 2023 Market Size | 2028 Market Size | CAGR (2023-2028) | |
| United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market | USD 54.21 billion | USD 68.32 billion | 4.74% |
Canada Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market revenue in Canada was valued at USD 5.67 billion in 2023. It is expected to reach USD 7.88 billion by 2028, growing at a CAGR of 6.79% during the forecast period (2023-2028). The pharmaceutical industry of Canada is one of the most innovative in terms of products. Pharmaceuticals, a key sector of the Canadian economy, is supported by the Canadian government, which provides a business-friendly environment for pharmaceutical companies and can leverage assets for short- and long-term business strategies.
-Market-Revenue-in-USD-Billion.png)
| 2023 Market Size | 2028 Market Size | CAGR (2023-2028) | |
| Canada Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market | USD 5.67 billion | USD 7.88 billion | 6.79% |
United Kingdom Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market revenue in United Kingdom was valued at USD 6.02 billion in 2023. It is expected to reach USD 7.07 billion by 2028, growing at a CAGR of 3.24% during the forecast period (2023-2028). The UK’s pharmaceutical and life sciences sector has pitched up well in the face of the covid crisis, with robust capitalization providing the structure for continued momentum despite the downturn. It was due to the backdrop of innovation, aided by a complex and wide-ranging network of government support, financial incentives, and other collaboration with research institutions and the National Health Service (NHS).
-Market-Revenue-in-USD-Billion.png)
| 2023 Market Size | 2028 Market Size | CAGR (2023-2028) | |
| United Kingdom Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market | USD 6.02 billion | USD 7.07 billion | 3.24% |
Germany Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market revenue in Germany was valued at USD 13.63 billion in 2023. It is expected to reach USD 17.41 billion by 2028, growing at a CAGR of 5.02% during the forecast period (2023-2028). Germany is likely to remain the largest contract manufacturing market in Western Europe, both in capacity and market share. One of the factors attracting pharmaceutical manufacturers to outsource production to this region is highly skilled and specialized employees, which is vital for manufacturing highly potent APIs (HPAPIs).
-Market-Revenue-in-USD-Billion.png)
| 2023 Market Size | 2028 Market Size | CAGR (2023-2028) | |
| Germany Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market | USD 13.63 billion | USD 17.41 billion | 5.02% |
France Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market revenue in France was valued at USD 11.18 billion in 2023. It is expected to reach USD 13.75 billion by 2028, growing at a CAGR of 4.22 % during the forecast period (2023-2028). Drug prices in France are lower than in other European countries as the French government bears most of the drug costs. Due to favorable reimbursement policies and high margins, the injectable segment is expected to experience a higher growth rate than other segments of its FDF manufacturing.
-Market-Revenue-in-USD-Billion.png)
| 2023 Market Size | 2028 Market Size | CAGR (2023-2028) | |
| France Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market | USD 11.18 billion | USD 13.75 billion | 4.22% |
China Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market revenue in China was valued at USD 27.12 billion in 2023. It is expected to reach USD 42.94 billion by 2028, growing at a CAGR of 9.63% during the forecast period (2023-2028). China is rapidly growing as the most attractive outsourcing country. Most CMOs operating in China mainly offer API and bulk drug product manufacturing for approved generic and branded drugs. Asymchem Laboratories, Beijing Second Pharmaceutical, Chongqing Huapont Pharmaceutical, Shandong Xinhua Pharmaceutical, Venturepharm Laboratories, Porton Fine Chemicals, and Tianjin Pharmaceutical are some of the top API and chemical intermediate CMOs in the nation.
-Market-Revenue-in-USD-Billion.png)
| 2023 Market Size | 2028 Market Size | CAGR (2023-2028) | |
| China Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market | USD 27.12 billion | USD 42.94 billion | 9.63% |
India Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market revenue in India was valued at USD 15.63 billion in 2023. It is expected to reach USD 26.73 billion by 2028, growing at a CAGR of 11.34% during the forecast period (2023-2028). The pharmaceutical sector in India produces a variety of bulk pharmaceuticals, which are active pharmaceutical ingredients that serve as the basic raw materials for formulations. Formulations comprise the remaining four-fifths of the industry's output, with bulk pharmaceuticals making up about one-fifth.
-Market-Revenue-in-USD-Billion.png)
| 2023 Market Size | 2028 Market Size | CAGR (2023-2028) | |
| India Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market | USD 15.63 billion | USD 26.73 billion | 11.34% |
Japan Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market revenue in Japan was valued at USD 4.59 billion in 2023. It is expected to reach USD 5.47 billion by 2028, growing at a CAGR of 3.57% during the forecast period (2023-2028). Japan has a significant position in the pharmaceutical world globally, where the country stands as the third-largest pharmaceutical market in the world. Many multinational corporations have found it difficult to enter the industry despite this. High entrance obstacles with a historically closed domestic market have limited options. The trend is beginning to change.
-Market-Revenue-in-USD-Billion.png)
| 2023 Market Size | 2028 Market Size | CAGR (2023-2028) | |
| Japan Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market | USD 4.59 billion | USD 5.47 billion | 3.57% |
Australia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market revenue in Australia was valued at USD 3.52 billion in 2023. It is expected to reach USD 4.45 billion by 2028, growing at a CAGR of 4.82% during the forecast period (2023-2028). Numerous pharmaceutical companies in Australia are struggling due to major regulatory reforms in drug pricing, structural adjustments, unpredictable reimbursement decisions, and pricing decisions. However, the nation is geographically well-positioned for pharmaceutical exports because of its proximity to South Asia's growing markets.
-Market-Revenue-in-USD-Billion.png)
| 2023 Market Size | 2028 Market Size | CAGR (2023-2028) | |
| Australia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market | USD 3.52 billion | USD 4.45 billion | 4.82% |
United Arab Emirates Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market revenue in the United Arab Emirates was valued at USD 0.79 billion in 2023. It is expected to reach USD 0.88 billion by 2028, growing at a CAGR of 2.33% during the forecast period (2023-2028). The UAE pharmaceutical industry is one of the most developed markets in the Middle Eastern region, armed with a robust healthcare infrastructure and the highest per capita medical spending. There has been a spurt in drug manufacturing activities by domestic producers in the United Arab Emirates.
-Market-Revenue-in-USD-Billion.png)
| 2023 Market Size | 2028 Market Size | CAGR (2023-2028) | |
| United Arab Emirates Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market | USD 0.79 billion | USD 0.88 billion | 2.33% |
South Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market revenue in South Africa was valued at USD 0.52 billion in 2023. It is expected to reach USD 0.67 billion by 2028, growing at a CAGR of 5.08% during the forecast period (2023-2028). South Africa is the largest CMO market in Africa. Some of the major factors responsible for South Africa’s attractive pharmaceutical contract manufacturing are its well-established and stable markets and high turnover to investments.
-Market-Revenue-in-USD-Billion.png)
| 2023 Market Size | 2028 Market Size | CAGR (2023-2028) | |
| South Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market | USD 0.52 billion | USD 0.67 billion | 5.08% |
Get 10-year market size data by segments and in-depth analysis on specific countries. Contact us now.
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Trends
Increasing Investment in R&D Drives the Market
- The United States is one of the largest pharmaceutical markets, accounting for about half of the R&D spending in the pharmaceutical and biotech markets. CMOs play a vital role in this market, investing in new facilities and technology to serve various outsourcing entities. Moreover, companies are not only reaping the benefits of their Asian footprint through in-house investments but are also looking for research-based partnerships to acquire high-end sourcing expertise, build drug discovery, and invest.
- For instance, in January 2024, EXO Biologics SA, a Belgian biotech company committed to developing biopharmaceuticals using exosomes to treat rare diseases with high unmet medical needs, launched ExoXpert, a contract development and manufacturing organization (CDMO) specializing in exosomes. ExoXpert offers an MSC-based exosome manufacturing platform used in European clinical trials and is a wholly-owned subsidiary of EXO Biologics.
- Proper infrastructure for the safe handling and containment of high-potency drugs, especially the need for appropriate analytical skills for high-potency drugs, and adequate project management (including good launch, execution, and completion) are needed to stand out in the market for research and development.
- As pharmaceutical companies shift their target toward scientific research and pharmaceutical marketing, CDMOs can further establish themselves as vital partners and build strategic, integrated partnerships with their customers.
- Given the rising number of complex and high-potency compounds, CDMOs can stand out through advanced technology and specialized expertise. In addition, new operational approaches such as continuous manufacturing are expected to allow CDMOs to improve the efficiency of their manufacturing processes, reducing costs and wastage.
- Furthermore, the market is witnessing growth in clinical trials, driving the demand. For instance, according to ClinicalTrials.gov, the total number of registered clinical studies was 437.513 million in 2022, reaching 477.237 million in 2023.
- CDMOs are anticipated to discover new opportunities with an increasing number of small and medium-sized pharma firms. Such small and medium-sized pharma companies are mainly accountable for the growing share of new drug approvals and often have no manufacturing capacity.
Asia-Pacific is Expected to be the Fastest-growing Region for the CRO Segment
- Asia-Pacific is anticipated to witness the highest growth in the CRO market over the forecast period due to the region's low cost compared to the United States and other developed economies. In addition, the growing incidences of chronic and lifestyle diseases, such as diabetes and heart disease, along with ease of patient recruitment and availability of expertise for clinical trials, are major driving factors boosting the growth in the region.
- For instance, China has over 180 million elderly citizens suffering from chronic diseases, of whom 75% have more than one, according to the National Health Commission (NHC). By 2030, cardiovascular disease are projected to cost the Chinese government USD 1,044 billion. Similar trends for the high prevalence of diabetes are present around Asia-Pacific, including China, South Korea, and Australia.
- With the increasing privatization of clinical trials, there has been an increase in research process outsourcing in developing countries such as China and India. For example, large pharmaceutical companies are increasingly outsourcing research services such as clinical data management, pharmacovigilance, biostatistics, etc.
- There are numerous reasons why certain regions attract organizations conducting clinical trials. Some include cost, patient recruitment, required testing, and shorter timelines. The overall number of clinical trials is increasing in China, India, and Japan, making Asia-Pacific one of the potential regions.
- India provides preclinical services at lower costs than developed nations. Initiatives taken by the Indian government to expand the CRO potential have offered an attractive market opportunity in recent years.
- The availability of scientific expertise in India may boost business growth over the next few years. Clinical trials in the country are about 50% less costly than in the United States. India is one of the largest drug producers and has the most FDA-approved manufacturing plants outside the United States, giving it a competitive edge over China.
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Industry Overview
The pharmaceutical CDMO market is highly fragmented. Major vendors account for the majority of the market share. The presence of many players impacts the pricing of services, making it a direct competing factor, especially for small-scale vendors. The vendors are expected to focus on delivering one-stop-shop services, providing them with a competitive advantage. These practices would be possible for the CMOs with access to significant capital. This factor increases the competition and acts as an entry barrier for new players. The market faces competition from other CROs and from a wide range of vendors, varying from cloud-based data management tool providers to individual solution providers. In countries where there is a high presence of pharma and biotech research activity, the competitive rivalry is especially high. Some of the major players in the market are Catalent Inc., Recipharm AB, Jubilant Pharmova Ltd, Patheon Inc. (Thermo Fisher Scientific Inc.), and Boehringer Ingelheim Group.
- In February 2024, Catalent Inc. and Novo Holdings entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at USD 16.5 billion.
- In February 2024, Recipharm, a contract development and manufacturing organization, entered into an exclusive licensing and collaboration agreement with Medspray and Resyca to develop soft mist nasal delivery devices for single and combination pharmaceutical products.
- In January 2024, Parexel and the Japanese Foundation for Cancer Research announced a strategic alliance to accelerate access to oncology clinical trials in Japan.
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Leaders
Catalent Inc.
Recipharm AB
Jubilant Pharmova Ltd
Patheon Inc. (Thermo Fisher Scientific Inc.)
Boehringer Ingelheim Group
*Disclaimer: Major Players sorted in no particular order
_Market_Concentration.webp)
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market News
- January 2024 - A new collaboration was announced jointly by FAMAR and Lavipharm, two leading pharmaceutical companies. FAMAR is a leading provider of development and manufacturing services for pharmaceutical and cosmetic products (CDMO) and one of the major CDMO players in Europe. Lavipharm is a research and development (R&D) company that manufactures, imports, sells, and distributes pharmaceuticals and healthcare products in Greece.
- January 2024 - Pluri, an Israeli biotechnology company, announced the launch of a new business division, “pluriCDMO," that will provide cell therapy manufacturing services as contract development and production organizations." The new division includes a 47,000-ft2 good manufacturing practice (GMP) cell therapy production facility.
- October 2023 - IQVIA announced a strategic collaboration with Argenx to advance the treatment of patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance (PV) safety services and solutions.
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET INSIGHTS
4.1 Market Overview
4.2 Industry Attractiveness - Porter's Five Forces Analysis
4.2.1 Porter's Five Forces Analysis for CMO
4.2.2 Porter's Five Forces Analysis for CRO
4.3 Industry Value Chain Analysis
4.4 Industry Policies
5. MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Outsourcing Volume by Big Pharmaceutical Companies
5.1.2 Advent of CDMO Model into the Market
5.1.3 Increasing Investment in R&D
5.2 Market Restraints
5.2.1 Increasing Lead Time and Logistics Costs
5.2.2 Stringent Regulatory Requirements
5.2.3 Capacity Utilization Issues Affecting the Profitability of CMOs
5.3 Emphasis on Solid-based Oral Dosage Formulations
5.4 Qualitative Coverage on the 3D Printing Developments in the OSD Segment
5.4.1 Evolution of 3D Printing in Fabrication Processes and the Key Advantages Over Conventional Processes
5.4.2 Analysis of Major Drugs Manufactured Using 3D Printing-based Process
5.4.3 Analysis of Key Techniques Deployed (SLS & FDM), Along with their Relative Advantages
5.4.4 Key Developments on Stakeholders
6. TECHNOLOGY SNAPSHOT
6.1 Dosage Formulation Technologies
6.2 Dosage Forms by Route of Administration
6.3 Key Considerations for Outsourcing of Pharmaceutical R&D
6.4 Major Segments in CRO Bio Analytical Testing, Central Laboratory Testing, and cGMP Testing
7. MARKET SEGMENTATION
7.1 By Service Type CMO Segment
7.1.1 Active Pharmaceutical Ingredient (API) Manufacturing
7.1.1.1 Small Molecule
7.1.1.2 Large Molecule
7.1.1.3 High Potency (HPAPI)
7.1.2 Finished Dosage Formulation (FDF) Development and Manufacturing
7.1.2.1 Solid Dose Formulation
7.1.2.1.1 Tablets
7.1.2.1.2 Others (Capsules, Powders, etc.)
7.1.2.2 Liquid Dose Formulation
7.1.2.3 Injectable Dose Formulation
7.1.3 Secondary Packaging
7.2 By Research Phase CRO Segment
7.2.1 Pre-clinical
7.2.2 Phase I
7.2.3 Phase II
7.2.4 Phase III
7.2.5 Phase IV
7.3 By Geography - Pharmaceutical CMO***
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.2 Europe
7.3.2.1 United Kingdom
7.3.2.2 Germany
7.3.2.3 France
7.3.2.4 Italy
7.3.3 Asia
7.3.3.1 China
7.3.3.2 India
7.3.3.3 Japan
7.3.3.4 Australia and New Zealand
7.3.4 Latin America
7.3.4.1 Brazil
7.3.4.2 Mexico
7.3.4.3 Argentina
7.3.5 Middle East and Africa
7.3.5.1 United Arab Emirates
7.3.5.2 Saudi Arabia
7.3.5.3 South Africa
7.4 By Geography - Pharmaceutical CRO
7.4.1 North America
7.4.2 Europe
7.4.3 Asia
7.4.4 Australia and New Zealand
7.4.5 Latin America
7.4.6 Middle East and Africa
8. VENDOR MARKET SHARE
9. COMPETITIVE LANDSCAPE
9.1 Company Profiles
9.1.1 Catalent Inc.
9.1.2 Recipharm AB
9.1.3 Jubilant Pharmova Ltd
9.1.4 Patheon Inc. (Thermo Fisher Scientific Inc.)
9.1.5 Boehringer Ingelheim Group
9.1.6 Pfizer CentreSource
9.1.7 Aenova Holding GmbH
9.1.8 Famar SA
9.1.9 Baxter Biopharma Solutions (Baxter International Inc.)
9.1.10 Lonza Group
9.1.11 Tesa Labtec GmbH (TESA SE)
9.1.12 Tapemark
9.1.13 ARX LLC
9.1.14 CMIC Holdings Co. Ltd
9.1.15 LabCorp Drug Development
9.1.16 Syneos Health Inc.
9.1.17 LSK Global Pharma Service Co. Ltd
9.1.18 Novotech Pty Ltd
9.1.19 PAREXEL International Corporation
9.1.20 Pharmaceutical Product Development LLC (Thermo Fisher Scientific Inc.)
9.1.21 PRA Health Sciences Inc. (Icon PLC)
9.1.22 Quanticate Ltd
9.1.23 IQVIA Holdings Inc.
9.1.24 SGS Life Science Services SA
9.1.25 Hangzhou Tigermed Consulting Co. Ltd
9.1.26 Samsung Bioepis Co. Ltd
9.1.27 WuXi AppTec Inc.
9.1.28 Sagimet Biosciences (3V Biosciences Inc.)
- *List Not Exhaustive
10. INVESTMENT SCENARIO
11. FUTURE OUTLOOK OF THE GLOBAL PHARMACEUTICAL CDMO MARKET
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Industry Segmentation
The study tracks and analyzes the demand for outsourcing CMO and CRO activities within the pharmaceutical industry based on the current trends and market dynamics. The market numbers are derived by tracking the revenue generated by the players operating in the market who are providing CRO & CMO services. The study provides a detailed breakdown of various research phases and service types. This report analyzes the factors based on the prevalent base scenarios, key themes, and end-user vertical-related demand cycles.
The pharmaceutical contract development and manufacturing organization market is segmented by service type CMO segment (active pharmaceutical ingredient (API) manufacturing (small molecule, large molecule, and high potency (HPAPI)), finished dosage formulation (FDF) development and manufacturing (solid dose formulation (tablets), liquid dose formulation, injectable dose formulation), secondary packaging), research phase CRO segment (pre-clinical, phase I, phase II, phase III, phase IV), pharmaceutical CMO geography (North America [United States, Canada], Europe [United Kingdom, Germany, France, Italy, and Rest of Europe], Asia-Pacific [China, India, Japan, Australia, and the Rest of Asia-Pacific], Latin America [Brazil, Mexico, Argentina, and the Rest of Latin America], and the Middle East and Africa [United Arab Emirates, Saudi Arabia, South Africa, and the Rest of Middle-East and Africa]), and pharmaceutical CRO geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa). The market sizes and forecasts are provided in terms of value USD for all the above segments.
| By Service Type CMO Segment | ||||||||
| ||||||||
| ||||||||
| Secondary Packaging |
| By Research Phase CRO Segment | |
| Pre-clinical | |
| Phase I | |
| Phase II | |
| Phase III | |
| Phase IV |
| By Geography - Pharmaceutical CMO*** | ||||||
| ||||||
| ||||||
| ||||||
| ||||||
|
| By Geography - Pharmaceutical CRO | |
| North America | |
| Europe | |
| Asia | |
| Australia and New Zealand | |
| Latin America | |
| Middle East and Africa |
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Research Faqs
How big is the Pharmaceutical Contract Development And Manufacturing Organization Market?
The Pharmaceutical Contract Development And Manufacturing Organization Market size is expected to reach USD 243.29 billion in 2024 and grow at a CAGR of 6.41% to reach USD 331.98 billion by 2029.
What is the current Pharmaceutical Contract Development And Manufacturing Organization Market size?
In 2024, the Pharmaceutical Contract Development And Manufacturing Organization Market size is expected to reach USD 243.29 billion.
Who are the key players in Pharmaceutical Contract Development And Manufacturing Organization Market?
Catalent Inc., Recipharm AB, Jubilant Pharmova Ltd, Patheon Inc. (Thermo Fisher Scientific Inc.) and Boehringer Ingelheim Group are the major companies operating in the Pharmaceutical Contract Development And Manufacturing Organization Market.
Which is the fastest growing region in Pharmaceutical Contract Development And Manufacturing Organization Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Pharmaceutical Contract Development And Manufacturing Organization Market?
In 2024, the North America accounts for the largest market share in Pharmaceutical Contract Development And Manufacturing Organization Market.
What years does this Pharmaceutical Contract Development And Manufacturing Organization Market cover, and what was the market size in 2023?
In 2023, the Pharmaceutical Contract Development And Manufacturing Organization Market size was estimated at USD 227.70 billion. The report covers the Pharmaceutical Contract Development And Manufacturing Organization Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Pharmaceutical Contract Development And Manufacturing Organization Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
What are the emerging trends in CDMO technology impacting the development process?
The emerging trends in CDMO technology that is impacting the development process are a) Advancements in areas like continuous manufacturing b) Bioprocessing
CDMO Industry Report
The global pharmaceutical CDMO market is on a significant upswing, fueled by the rising demand for generic drugs, advancements in manufacturing technologies, and the need for efficient drug development processes. This growth is propelled by the high costs of in-house drug development, leading pharmaceutical companies to outsource to CDMOs, which offer comprehensive services ensuring quality and regulatory compliance. The sector is further boosted by investments in R&D, aiming to meet the demand for novel therapies. Despite challenges like varying regulatory requirements, opportunities in emerging markets promise substantial growth, due to cost advantages and a skilled workforce. North America leads the market, supported by a strong pharmaceutical sector and increased research funding. With a focus on technological innovations and emerging markets, the pharmaceutical CDMO industry is poised for expansion. For detailed insights, Mordor Intelligence™ provides an in-depth analysis, including market share, size, revenue growth rate, and a forecast outlook, available as a free report PDF download, highlighting the sector's potential and opportunities for growth.
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Report Snapshots
- Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Size
- Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Share
- Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Trends
- Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Companies
